Article Versions Notes

Sawada K, Nakayama K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Kanno K, Sato S, Nakayama S, Otsuki Y, et al. Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare. 2023; 11(8):1073. https://doi.org/10.3390/healthcare11081073

Sawada, Kiyoka, Kentaro Nakayama, Sultana Razia, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Kosuke Kanno, Seiya Sato, Satoru Nakayama, Yoshiro Otsuki, and et al. 2023. "Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status" Healthcare 11, no. 8: 1073. https://doi.org/10.3390/healthcare11081073

Sawada, K., Nakayama, K., Razia, S., Yamashita, H., Ishibashi, T., Ishikawa, M., Kanno, K., Sato, S., Nakayama, S., Otsuki, Y., & Kyo, S. (2023). Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare, 11(8), 1073. https://doi.org/10.3390/healthcare11081073